Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251185 | 0.87 | DGAT1 (0.65) | DGAT1KDM4EMAPTNPSR1CA9 | |
| SCHEMBL15252653 | 0.86 | KDM4E (0.52) | DGAT1KDM4EMAPTNPSR1CA9 | |
| SCHEMBL1250303 | 0.84 | DGAT1 (0.73) | DGAT1MAPTKDRHDAC3HDAC7 | |
| SCHEMBL1250721 | 0.83 | DGAT1 (0.59) | DGAT1MAPTCHEK1NR2E3 | |
| SCHEMBL1250120 | 0.83 | DGAT1 (0.73) | DGAT1KDRHDAC3HDAC7HDAC10 | |
| SCHEMBL1249086 | 0.81 | DGAT1 (0.79) | DGAT1MAPTKDRCHEK1NR2E3 | |
| SCHEMBL1250358 | 0.80 | DGAT1 (0.71) | DGAT1KDM4EMAPTKMT2AKDR | |
| SCHEMBL1251551 | 0.79 | DGAT1 (0.69) | DGAT1KDM4EMAPTNPSR1CA9 | |
| SCHEMBL1249997 | 0.78 | DGAT1 (0.82) | DGAT1KDM4EMAPTKMT2AKDR | |
| SCHEMBL1250649 | 0.78 | DGAT1 (0.80) | DGAT1KDRCHEK1NR2E3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885KDM4E 4129/4885MAPT 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.